The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

INOVIO (NASDAQ: INO) has released its financial results for the third quarter of 2024, alongside updates on significant ...

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics License Application (BLA) in the U.S. for ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

The primary endpoint of achieving microdystrophin expression of at least 10% was met by all participants in the current trial phase, suggesting a high probability of positive outcomes for the pivotal ...

Stryker , a global leader in medical technologies, unveiled the Oculan Lighting Platform, an innovative lighting solution designed to provide consistent, high-quality illumination, allowing surgeons ...

Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...

This dual-track strategy enables Dyadic to capitalize on near-term milestones, generating license revenue and achieving ...

HCW Biologics shares skyrocketed as the company entered a licensing agreement with China's WY Biotech for an immunotherapeutic product candidate.